GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » ROE %

Scancell Holdings (LSE:SCLP) ROE % : 0.00% (As of Apr. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Scancell Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Scancell Holdings's annualized net income for the quarter that ended in Apr. 2024 was £-6.62 Mil. Scancell Holdings's average Total Stockholders Equity over the quarter that ended in Apr. 2024 was £-5.93 Mil. Therefore, Scancell Holdings's annualized ROE % for the quarter that ended in Apr. 2024 was N/A%.

The historical rank and industry rank for Scancell Holdings's ROE % or its related term are showing as below:

LSE:SCLP's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.68
* Ranked among companies with meaningful ROE % only.

Scancell Holdings ROE % Historical Data

The historical data trend for Scancell Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings ROE % Chart

Scancell Holdings Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.83 -189.48 -90.64 - -

Scancell Holdings Semi-Annual Data
Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -129.14 -117.87 -483.30 - -

Competitive Comparison of Scancell Holdings's ROE %

For the Biotechnology subindustry, Scancell Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's ROE % falls into.



Scancell Holdings ROE % Calculation

Scancell Holdings's annualized ROE % for the fiscal year that ended in Apr. 2024 is calculated as

ROE %=Net Income (A: Apr. 2024 )/( (Total Stockholders Equity (A: Apr. 2023 )+Total Stockholders Equity (A: Apr. 2024 ))/ count )
=-5.859/( (-9.648+-3.505)/ 2 )
=-5.859/-6.5765
=N/A %

Scancell Holdings's annualized ROE % for the quarter that ended in Apr. 2024 is calculated as

ROE %=Net Income (Q: Apr. 2024 )/( (Total Stockholders Equity (Q: Oct. 2023 )+Total Stockholders Equity (Q: Apr. 2024 ))/ count )
=-6.622/( (-8.363+-3.505)/ 2 )
=-6.622/-5.934
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Apr. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Scancell Holdings  (LSE:SCLP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Apr. 2024 )
=Net Income/Total Stockholders Equity
=-6.622/-5.934
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6.622 / 0)*(0 / 22.914)*(22.914 / -5.934)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Apr. 2024 )
=Net Income/Total Stockholders Equity
=-6.622/-5.934
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-6.622 / -11.058) * (-11.058 / -20.294) * (-20.294 / 0) * (0 / 22.914) * (22.914 / -5.934)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.5988 * 0.5449 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is two times the semi-annual (Apr. 2024) net income data. The Revenue data used here is two times the semi-annual (Apr. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Scancell Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings Headlines

No Headlines